1. Home
  2. CIA vs HELP Comparison

CIA vs HELP Comparison

Compare CIA & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens Inc. ($1.00 Par)

CIA

Citizens Inc. ($1.00 Par)

HOLD

Current Price

$5.41

Market Cap

251.0M

Sector

Finance

ML Signal

HOLD

HELP

Cybin Inc. Common Stock

N/A

Current Price

$5.50

Market Cap

249.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CIA
HELP
Founded
1969
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.0M
249.0M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
CIA
HELP
Price
$5.41
$5.50
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$51.50
AVG Volume (30 Days)
115.4K
625.6K
Earning Date
05-07-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$255,616,000.00
N/A
Revenue This Year
$3.10
N/A
Revenue Next Year
$4.47
N/A
P/E Ratio
$28.23
N/A
Revenue Growth
4.33
N/A
52 Week Low
$3.25
$4.29
52 Week High
$6.40
$8.55

Technical Indicators

Market Signals
Indicator
CIA
HELP
Relative Strength Index (RSI) 56.51 53.34
Support Level $5.10 $4.40
Resistance Level $5.50 $8.55
Average True Range (ATR) 0.26 0.30
MACD 0.09 0.15
Stochastic Oscillator 77.11 87.50

Price Performance

Historical Comparison
CIA
HELP

About CIA Citizens Inc. ($1.00 Par)

Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

Share on Social Networks: